Batna Journal of Medical Sciences
Volume 13, Numéro 4, Pages 336-341
2026-06-10

Generalized Acquired Myasthenia Gravis Triggered By Sars-cov-2 Infection: A Case Report And Literature Review

Authors : Laouar Leila . Dammene Debbih Nadia . Arzour Hind . Haddouche Assia . Nouioua Sonia .

Abstract

The emergence of cases of myasthenia gravis (MG) following SARS-CoV-2 infection suggests a potential triggering role of COVID-19 in the development of this autoimmune disorder. A 33-year-old woman with a family history of autoimmune disease developed generalized MG five days after mild COVID-19. Initial symptoms included progressive fatigable limb weakness following resolution of respiratory manifestations. Electrophysiological studies demonstrated impaired neuromuscular transmission on repetitive nerve stimulation, and serum anti–acetylcholine receptor (AChR) antibodies were positive, confirming the diagnosis of generalized MG. The early presentation initially raised the differential diagnosis of post-COVID fatigue syndrome. Psychological assessment showed mild-to-moderate anxiety and depressive symptoms (Hospital Anxiety and Depression Scale scores: anxiety 12/21; depression 11/21), which may have contributed to delayed recognition of neuromuscular symptoms. The patient received pyridostigmine followed by intravenous immunoglobulins, with marked clinical improvement, and subsequently underwent thymectomy. At 12-month follow-up, she remained asymptomatic without recurrence. Post-COVID-19 MG appears to represent an emerging autoimmune neurological entity with distinct clinical and immunological characteristics. Early recognition is essential in patients presenting with persistent fluctuating weakness after SARS-CoV-2 infection. Further longitudinal studies are needed to clarify the immunopathogenic mechanisms and long-term outcomes of this condition.

Keywords

Myasthenia gravis ; COVID-19 ; Post-COVID fatigue ; Autoimmunity ; Anti-AChR antibodies ; Thymectomy